Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients

Contributed by: PR Newswire

Tags

CAMURUS-AB-study

More Like This

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK

CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU

Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU

Camurus reports positive topline results for CAM2056, semaglutide monthly depot

Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis

PR Newswire associated0

Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis